Introduction
============

Polycystic ovarian syndrome (PCOS) is a common endocrine disorder affecting 6%--7% of the population ([@b66]; [@b34]; [@b8]; [@b11]). It is characterized by chronic anovulation and hyperandrogenism with the clinical manifestation of oligomenorrhoea, hirsutism, and acne ([@b45]). In January 2004, the European Society for Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM) co-sponsored the Rotterdam polycystic ovary syndrome consensus workshop that published diagnostic guidelines, building on the consensus statement of the National Institutes of Health 1990 (ESHRE/ASRM-Sponsored_PCOS_Consensus_Workshop_Group 2004). The Rotterdam criteria for the diagnosis of PCOS states 2 of the 3 features needs to be present to make the diagnosis and with the exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome). These features includes (1) Oligo- or anovulation (2) Clinical and/or biochemical signs of hyperandrogenism and (3) Polycystic ovaries (either 12 or more follicles measuring 2--9 mm in diameter, or an ovarian volume of \>10 cm^3^) ([@b14]).

It has now been recognized that the diagnosis of metabolic syndrome identifies patients at increased risk of developing cardiovascular disease, and attempts have been made to develop the most convenient and useful criteria for the diagnosis of this condition in clinical practice. With the pathogenesis of metabolic syndrome not well understood, central obesity and insulin resistance are acknowledged as important causative factors ([@b5]; [@b25]; [@b79]). The most recent International Diabetes Federation consensus, however, has developed a new definition emphasizing the importance of central obesity with modifications according to ethnic groups ([@b3]). Previous definitions from the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III), USA (NCEP/ATPIII 2001) and the World Health Organization (WHO) had emphasized insulin resistance ([@b4]; [@b52]).

It would appear that many women with PCOS fulfil the criteria for the metabolic syndrome in view of a higher reported incidence of hypertension, dyslipidemia, visceral obesity, insulin resistance and hyperinsulinemia in this population ([@b49]). It is recognized that insulin resistance and compensatory hyperinsulinemia not only contribute to hyperglycemia, but they also have a pathophysiological role in the development of the cardio-metabolic state ([@b72]).

Metabolic abnormalities of PCOS
===============================

Hyperinsulinemia and insulin resistance
---------------------------------------

Insulin binds to its receptor on the cell membrane facilitating the delivery of glucose across the membrane by enhancing the expression of GLUT transporters ([@b105]). Disturbance in insulin's ability to bind to its receptor, or the transport mechanism across the cell membrane may lead to a state of reduced sensitivity to insulin, or insulin resistance. Studies suggest that insulin induced receptor autophosphorylation is markedly diminished in approximately 50% of PCOS women. In those PCOS women who have normal receptor autophosphorylation, it remains likely that signalling mechanism downstream of the receptor are abnormal ([@b36]). In addition to decreased insulin sensitivity, pancreatic β-cell secretory dysfunction has also been reported ([@b40]; [@b37]). Furthermore, a reduction in hepatic insulin extraction resulting in a reduction of insulin clearance rate may also contribute to the high insulin levels ([@b71]; [@b82]).

Insulin stimulates lipogenesis in arterial tissue and adipose tissue via an increased production of acetyl-Co A, and the entry of glucose and triglycerides ([@b87]). Dyslipidemia associated with high levels of triglycerides and low levels of HDL cholesterol in cardiometabolic syndrome are attributed to the effect of insulin on cholesterol ester transfer protein that promotes the transfer of cholesterol from HDL to VLDL and resultant catabolism of Apo lipoprotein A ([@b107]; [@b29]). As insulin increases the levels of HMG Co A reductase, the rate-limiting enzyme in the synthesis of cholesterol, it may contribute to the raised cholesterol level that is also a feature of hyperinsulinemia ([@b35]).

Loss of peroxisome proliferator activated nuclear receptor (PPAR) gamma has been linked to the development of severe insulin resistance, diabetes, and hypertension ([@b28]). Although both metformin and the thiazolidinediones act as insulin sensitizers, one recent study suggested that only rosiglitazone, but not metformin, increased the expression of PPAR gamma in peripheral tissue ([@b110]) thereby increasing peripheral insulin sensitivity. This may suggest that the thiazolidinediones may have additional peripheral benefits compared with metformin.

Visceral obesity
----------------

The prevalence of obesity in PCOS varies widely, between approximately 10--50% ([@b13]; [@b22]). Obese PCOS have lower levelsof luteinizing hormone (LH), sex hormone binding globulin (SHBG), dehydroepiandrosterone (DHEAS), dihydrotestosterone, free insulin-like growth Factor (IGF)-I, high-density lipoprotein, and higher low-density lipoprotein, compared with the nonobese PCOS group ([@b100]). However, the situation is complex; not all obese people are insulin resistant and not all who are insulin resistant are obese. Gluteo-femoral obesity is less associated with insulin resistance than is central or android obesity ([@b15]). A state of hyperinsulinemia may itself contribute to obesity by the anabolic effect on fat metabolism through adipogenesis with increased uptake of glucose into adipocytes, the production of triglycerides and inhibition of hormone sensitive lipase ([@b7]).

Hypertension
------------

Hyperinsulinemia may contribute to the hypertension of the cardiometabolic syndrome by enhanced sodium retention ([@b123]), causing an increased intracellular sodium and calcium ([@b91]), and stimulation of the sympathetic nervous system ([@b75]; [@b97]).

Insulin also stimulates the release of IGF-1 that may contribute to the development of hypertension by causing vascular smooth muscle hypertrophy. Current evidence on prevalence of hypertension in patients with PCOS are conflicting at present with some studies suggesting a higher prevalence in this population ([@b114]; [@b41]; [@b83]; [@b55]), but not by others ([@b30]; [@b125]; [@b96]). A large long-term follow-up study by [@b117]) suggested an increased prevalence of hypertension in patients with PCOS, but with no increased risk of mortality and morbidity from coronary heart disease.

Dyslipidemia
------------

Data are conflicting on whether women with PCOS have a characteristic dyslipidemia. Studies have reported decreased levels of the cardioprotective high-density cholesterol lipoprotein (HDL-C), and elevated levels of triglycerides ([@b90]; [@b92]; [@b31]; [@b56]; [@b116]; [@b68]), although in one study HDL was elevated ([@b69]). Of concern, dyslipidemia has been found at puberty in studies on adolescent girls with a history of premature pubarche ([@b64]) and the metabolic disturbances can often be detected in the prepubertal period and throughout puberty ([@b59]). This dyslipidemia is seen in both lean and obese PCOS ([@b119])

Pro-thrombotic state
--------------------

Hyperinsulinemia contributes to the prothrombotic state by reducing fibrinolysis and raising the level of plasminogen activator inhibitor (PAI-1) ([@b88]). In patients with PCOS, the level of PAI-1 was found to be elevated ([@b9]; [@b96]; [@b120]), and it decreased with improvement in insulin sensitivity, either through weight loss ([@b6]) or the use of insulin sensitizing agents ([@b39]; [@b112]). The increase in PAI-1 activity in PCOS was thought to be independent of body mass index since elevated levels were also observed in lean PCOS women. Moreover, the increased level of PAI activity in PCOS was directly correlated with insulin resistance, thus implicating it as a contributing cardiovascular risk factor ([@b109]). However, other studies disagree ([@b10]; [@b33]).

Risk of type 2 diabetes
-----------------------

PCOS is commonly detected in a younger age group and is associated with a high risk of progression to type 2 diabetes and impaired glucose tolerance. For example, in one study, 35% of patients with PCOS had impaired glucose tolerance and 10% had type 2 diabetes by the age of 40 ([@b38]). A history of type 2 diabetes in a first-degree relative appears to define a subset of PCOS subjects with a greater prevalence of insulin secretory defects. The risk of developing type 2 diabetes through increased insulin resistance in PCOS may be enhanced by the defects described in insulin secretion ([@b40]).

A unique defect in serine phosphorylation of the insulin receptor that resulted in decreased activation of the receptor has been identified in about 50% of women with PCOS ([@b124]). Furthermore, serine phosphorylation of *CYP17* (Cytochrome P450, subfamily XVII), may also be part of the mechanism of increased adrenal androgen synthesis implicating serine phosphorylation an important process in the PCOS phenotype. The *CYP17* gene encodes the cytochrome *P450c17* enzyme which mediates the 17α-hydroxylation of pregnenolone and progesterone, and subsequent conversion of these 17-hydroxylated products to the estradiol precursors DHEA and androstenedione. In addition, familial PCOS has been linked to an insulin regulatory locus on chromosome 11 ([@b115]). Whether this represents a common genetic defect in PCOS and diabetes or whether it reflects co-segregation of diabetes with PCOS in the tested families, remains to be determined.

Sleep apnea
-----------

Sleep apnea is an independent cardiovascular risk factor that has been found to be more common in PCOS, the difference remained significant even when controlled for body mass index (BMI) ([@b51]; [@b44]). It was reported that the strongest predictors for sleep apnoea were fasting plasma insulin and glucose-to-insulin ratios ([@b113]).

Atherosclerosis
---------------

The presence of cardiovascular risk factors of obesity, insulin resistance and dyslipidemia may predispose women with PCOS to coronary heart disease, although this remains controversial:

### Angiography

One report evaluated 143 women age less than 60 years old undergoing cardiac catheterization for the investigation of chest pain. Polycystic ovarian morphology was present in 42% of women, and was associated with hirsutism, lower levels of HDL cholesterol, and higher concentrations of free testosterone, triglyceride, and C-peptide. The women with polycystic ovaries had more extensive coronary disease on angiography than those with normal ovaries ([@b18]). However, this study only examined at the association between ultrasound evidence of polycystic ovaries alone (rather than the full Rotterdam consensus definition of PCOS) and the extent of coronary disease on cardiac catheterization.

### Carotid ultrasound

A predisposition toward atherosclerosis was suggested in an ultrasonographic study of 16 women with PCOS aged over 40 years, where carotid artery intima-media thickness (IMT) was significantly greater than in normal controls ([@b53]). However, the mean IMT in the PCOS group was still well below that seen in patients with significant carotid artery disease. In another study with a larger cohort of subjects, the same group of researchers reported that among women aged 45 years or above, patients with PCOS had significantly greater mean carotid IMT than women in the control group ([@b108]).

### Endothelial dysfunction

Endothelial dysfunction is associated with the development of atherosclerosis ([@b27]). A positive correlation was demonstrated between abnormal endothelial function and testosterone levels in hyperandrogenic insulin-resistant women with PCOS, an association that was stronger than that of insulin sensitivity ([@b86])**.** Conversely, others have reported no differences in surrogate markers including endothelial function for increased cardiovascular risk in PCOS compared with weight-matched controls ([@b17]).

Several mechanisms may be involved in the development of endothelial dysfunction, such as reduced synthesis and release of nitric oxide (NO) ([@b62]), enhanced inactivation of NO after its release from endothelial cells ([@b19]) or enhanced synthesis of vasoconstricting agents ([@b16]). It has been demonstrated that insulin exerts a direct hypertrophic effect on the vascular endothelium and the smooth muscle cells. It has been found that in the skeletal muscle circulation insulin stimulates both endothelin-1 and NO activity, and an imbalance between the release of these two substances may be involved in the pathophysiology of endothelial dysfunction. Recent studies suggested that CRP directly promotes the atherosclerotic processes and endothelial cell inflammation leading to atherothrombosis ([@b101]).

### Long-term risk

In the Nurses' Health Study, a history of menstrual cycle irregularity was associated with an increased risk of non-fatal and fatal coronary heart disease ([@b102]). This might be explained by a high rate of PCOS with its associated metabolic disturbances in these women, although no other clinical or biochemical androgen data was available to confirm that menstrual irregularity was due to PCOS.

Despite the increase in cardiovascular risk factors including diabetes, hypertension, raised plasma cholesterol and BMI \>30, morbidity and mortality from of coronary heart disease among women with PCOS in a long-term study has not proved to be as high as previously predicted ([@b118]).

One recent observation showed no difference in surrogate markers of cardiovascular risk between PCOS and weight-matched controls (glucose, lipid, lipoprotein, sialic acid, fibrinogen, CRP, reactive hyperemic forearm blood flow) ([@b17]). However, in contrast, in another study patients with PCOS were found to have elevated triglycerides and cholesterol but no differences in CRP or 24 hour BP were observed. In addition, they also demonstrated that patients with PCOS had increased arterial stiffness measured by pulse wave velocity (PWV) and reduced brachial artery flow mediated vasodilatation (FMD), a marker of endothelial function ([@b73]). Whether these differences could have been accounted for by differing patient selection is unclear.

In summary, cardiovascular disease studies in PCOS have been inconclusive with some suggesting increased cardiac events among women with PCOS whilst other studies suggesting no increase compared with normal cycling women. This could be due to small sample size in the studies and variation in the characteristics of patients recruited. It has been suggested that patients with PCOS as defined by hyperandrogenemia plus either of oligomenorrhoea or polycystic ovaries on ultrasound may have a slight increase in cardiovascular risk profile as compared with those with only oligomenorrhoea and polycystic ovaries without hyperandrogenemia.

The role of adipocyte in cardiometabolic syndrome
=================================================

Adipose tissue has traditionally been considered an energy storage organ, but over the last decade a novel role of the adipose tissue as an endocrine organ has emerged ([@b74]; [@b104]; [@b47]). Adipocytes are metabolically active cells which secrete tumor necrosis factor alpha, interleukin 6, plasminogen activator inhibitor-1, leptin, resistin, adiponectin, and angiotensinogen ([@b93]; [@b122]).

Leptin is secreted mainly by adipose tissue and deficiency in leptin results in hyperphagia, decreased energy expenditure and morbid obesity ([@b46]). However, in terms of human obesity, leptin deficiency is rare. It has been postulated that leptin activates the sympathetic nervous system and is involved in blood pressure regulation, brain and bone development, hematopoiesis and wound healing ([@b1]).

It has been suggested that the function of leptin is to control the deposition of fat and this modulates its harmful accumulation in tissues such as heart, liver and kidneys. Leptin is involved in the control of vascular tone by stimutaneously producing a pressor action and opposing the nitric oxide mediated relaxing function ([@b48]). This may contribute to the hypertension associated with cardiometabolic syndrome. A positive relationship between insulin resistant PCOS women (both obese and non-obese) and hyperleptinemia, regardless of the BMI has been suggested in one study ([@b21]).

Increasing adipose tissue mass is associated with increasing levels of angiotensin II from the increased secretion of angiotensinogen by adipose tissue. Increase in angiotensin II could contribute to hypertension and aggravate insulin resistance ([@b42]).

IL-6 inhibits liproprotein lipase activity, enhances aromatase activity and increases the hepatic production of triglycerides ([@b80]). IL-6 is stimulated by TNF-alpha: TNF stimulates C-reactive protein that has been found to be correlated with obesity, insulin resistance, endothelial dysfunction, and therefore cardiovascular risk, and patients with PCOS have been shown to have a higher level of CRP ([@b63]; [@b12]). TNF-alpha also suppresses lipoprotein lipase and its release is inhibited by the thiazolidinediones and in PCOS, serum TNF-alpha is increased irrespective of obesity ([@b50]). Elevation of these inflammatory markers are in accord with the hypothesis that atheroma formation is primarily an inflammatory condition.

Adiponectin is secreted exclusively by adipocytes and levels are reduced in obesity, type 2 diabetes and coronary heart disease. Studies suggest an important link with insulin resistance ([@b106]) and adiponectin also inhibits vascular smooth muscle proliferation and the expression of adhesion molecules. Levels of adiponectin are increased by weight reduction and by thiazoledinediones ([@b121]). It has recently been shown that a significant reciprocal correlation exists between adiponectin and resistin independent of insulin resistance in women with PCOS ([@b70]). Resistin is implicated in the pathogenesis of Type 2 diabetes and obesity ([@b98]) where circulating resistin levels and resistin expression in adipocytes are increased. However, the role of resistin in patients with PCOS and thus cardiovascular risk in this group is still debatable. In one study, serum resistin level in patients with PCOS were no different to matched controls but resistin mRNA levels were 2-fold higher in omental adipocytes from PCOS patients ([@b98]). Others have reported that there is an increase in serum resistin level in patients with PCOS ([@b76]), although it has been suggested that this increase is dependent on BMI ([@b85]). Against this argument is that in BMI matched patients, serum resistin was found not to be different compared with controls ([@b23], [@b24]). Therefore more studies will be required to determine its importance in patients with PCOS.

Therapy of PCOS
===============

The effective treatment of patients with PCOS requires that the specific goal(s) of the therapy be first established. Individual goals may include fertility, treatment for hirsutism and/or acne, achieving a regular menstrual cycle, weight reduction, and the prevention of the long-term consequences associated with PCOS (type 2 diabetes, dyslipidemia, and possibly cardiovascular disease) or all of the above!

Treatments discussed here will focus on those aimed at modifying the cardiometabolic aspects of PCOS.

Exercise and diet
-----------------

Although obesity is not thought to be the cause for PCOS, it may exacerbate this dysfunction ([@b55]). Loss of significant weight has been reported to result in spontaneous resumption of ovulation ([@b32]), improvement in fertility ([@b81]), increased SHBG, and reduced basal level of insulin ([@b58]; [@b111]).

Data from the Diabetes Prevention Program (DPP) showed the importance of weight reduction in patients with impaired glucose tolerance that were at high risk of developing diabetes This study showed that both metformin therapy and intensive lifestyle intervention reduced the risk of developing diabetes (by 31% and 58%, respectively, in comparison with placebo), and both interventions were suggested to be cost-effective on the basis of computer projected lifetime risk ([@b89]). In accord with that is the observation that significant weight loss, ie, \>15% of body weight, has been found to improve the metabolic profile of PCOS women ([@b65]).

Insulin sensitizers
-------------------

### Metformin

Metformin is effective in the treatment of metabolic syndrome and modestly increases menstrual regularity and ovulation, and may improve hirsutism in patients with PCOS ([@b54]). Metformin treatment in lean women with PCOS also improves insulin resistance and hyperandrogenism without a change in BMI ([@b78]). Whilst metformin appearsto induce cardio-protective effects on serum insulin ([@b95]), serum lipids ([@b60]), and PAI-1 ([@b103]), the actual protection from long-term mortality and morbidity of cardiovascular disease has yet to be demonstrated. In addition, it has been suggested that metformin has a beneficial effect on endothelial function in patients with polycystic ovarian syndrome ([@b84]).

### Thiazolidinediones

Pioglitazone and rosiglitazone have also shown positive cardiometabolic effects, reducing hyperandrogenemia, and hirsutism as well as regulating the menstrual cycle in women with PCOS ([@b20]; [@b99]; [@b26]). Rosiglitazone was found to markedly reduce liver fat, increase insulin clearance, double adiponectin concentrations, and unlike metformin, it also increases peripheral insulin sensitivity ([@b110]). However, thiazolidinediones causes weight gain that may not be a desireable effect in this population of young women whose initial presenting complaint may well be the inability to lose weight.

Orlistat
--------

Orlistat, a pancreatic lipase inhibitor, limits the absorption of dietary fat. We have recently shown that it significantly reduced body weight and that there was a reduction in total testosterone levels in PCOS women equal to that of metformin ([@b61]). In women with PCOS, weight loss is associated with an improvement in insulin sensitivity and a reduction of the insulin concentration in the plasma ([@b2]). Therefore weight reduction with orlistat would be a suitable adjunct to insulin sensitizers in the treatment of patients with PCOS.

Sibutamine
----------

Sibutramine, a selective serotonin and adrenergic reuptake inhibitor, has shown positive effects on hyperandrogenemia, and clinical metabolic risk factors for cardiovascular disease in obese women with PCOS ([@b94]). However, sibutramine has to be prescribed with care in patients with hypertension, and in patients with PCOS, metformin may be a more effective treatment in the prompt restoration of ovarian function as compared with sibutramine ([@b67]).

In summary, cardiovascular disease studies in PCOS have been inconclusive, with some suggesting an increased in cardiac events among women with PCOS whilst others showed no difference. The mainstay of treatment is the encouragement of diet and exercise augmented by weight reducing medication and use of insulin sensitizers like metformin. Insulin sensitisers have beneficial effects on menstrual regularity, but their use specifically for potential cardio-protection needs to be clarified.
